Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INS062
- Development stage
- Phase 1
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Administration
- Subcutaneous
01
Overview
INS062 is a recombinant polypeptide drug developed as an insulin receptor (INSR) modulator for the treatment of diabetes mellitus. It is being investigated primarily for its bioequivalence to NovoRapid (insulin aspart), suggesting it is a rapid-acting insulin analog or biosimilar candidate. The drug acts by modulating the insulin receptor to regulate glucose metabolism and lower blood sugar levels. Clinical trials have focused on pharmacokinetics, pharmacodynamics, and safety in healthy subjects through subcutaneous injection[1][2][10].
- Other names
- INS062 injectionINS-062 injectionINS 062 injection
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on INS062.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INS062.